Secukinumab
novartis
['hidradenitis', 'novartis']
novartis presents late-breaking data from pivotal phase iii trials in patients with hidradenitis suppurativa (hs) at #eadvcongress. #eadv #novartisnews
The official account for @Novartis News & Media Updates. For media inquiries: media.relations@novartis.com. See our community guidelines: https://t.co/b4Kyh4UvNm